About US
Contact us
Position：Home > Phexcom News >
-
Compounder targets Turing's now-pricey Daraprim with $1-per-pill alternativeEarlier this week, presidential candidateHillary Clintoncalled on theFDAto speed copycat versions of the now-notorious toxoplasmosis med Daraprim to market. Now, a compounding pharmacy has stepped up2015/10/23
-
Does new scrutiny threaten pharma's specialty-pharmacy strategy?Yesterday's Valeant Pharmaceuticals rout put specialty pharmacies under an unwelcome spotlight. But though Valeant's own close relationship with Philidor RX may be an unusual one--a host of Big Pharma2015/10/23
-
FDA issues warning on AbbVie hep C drugs and drugmaker's shares fall 10%AbbVie'sViekira Pakand Technivie were developed to cure hepatitis C and so avoid the complications like liver transplants that can result from the disease. But the FDA said today that in some cases th2015/10/23
-
Michigan governor urges Perrigo shareholders to reject Mylan's offerSome of Perrigo's ($PRGO) shareholders have already spoken out against Mylan's ($MYL) hostile pursuit of the company. But now, Michigan Governor Rick Snyder is getting on board. Michigan Go2015/10/22
-
Teva mulls $7B stock offering to help fund Allergan generics buyTeva's ($TEVA) $40.5 billion deal for Allergan's ($AGN) generics company is going to help Allergan pay down much of its dealmaking debt. But in the meantime, the Israeli pharma needs some acquisition2015/10/22
-
Valeant shares nosedive on short seller's 'phantom sales' allegationsValeant has faced its fair share of questions from lawmakers, prosecutors and presidential candidates over the past several weeks--and now, it's facing a whole lot more from investors. The company's2015/10/22
-
Valeant changes its spots with promises to limit price hikes, spend more on R&DValeant changes its spots with promises to limit price hikes, spend more on R&D October 20, 2015 | ByCarly Helfand SHARE Tweet TOOLS Comment Print Contact Author Reprint2015/10/21
-
GOP's Rubio joins the pharma-bashing trend, slamming 'profiteering' on price hikesGOP's Rubio joins the pharma-bashing trend, slamming 'profiteering' on price hikes October 20, 2015 | ByTracy Staton Sen. Marco Rubio The drug-pricing debate has moved to the Republ2015/10/21
-
With Opsumit launch rolling, Actelion doesn't 'need' M&A: CEOWith Opsumit launch rolling, Actelion doesn't 'need' M&A: CEO October 20, 2015 | ByCarly Helfand Back in 2013,ActelionlaunchedOpsumit, a new-and-improved pulmonary arterial hypertension (P2015/10/21
-
Influential cancer group rolls out first set of 'affordability' ratings on cancer drugsStruggling Daiichi plots another 1,000-plus job cuts in U.S. October 19, 2015 | ByTracy Staton SHARE Tweet TOOLS Comment Print Contact Author Reprint Daiichi Sankyo's2015/10/20